-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The 2021 American Annual Meeting of Hematology (ASH) will be held online and offline (Atlanta) on December 11-14.
As a global event in the field of blood, it will attract the release and display of research results from the field of blood from all over the world every time , The research results of Chinese scholars are also increasing
.
Here we invite Professor Li Caixia from the First Affiliated Hospital of Soochow University to bring us the preliminary results of a study on relapsed and refractory B-cell non-Hodgkin’s lymphoma (R/R B-NHL) at the ASH conference 1
.
Study speed reading: The study included 11 patients who were treated with the anti-PD-1 antibody tislelizumab on the first day after continuous infusion of CD19/CD22 CAR-T cells.
The median follow-up was 5.
8 months.
The overall response rate ( ORR) was 81.
8% (9/11), complete remission (CR) rate was 72.
7% (8/11), 6-month progression-free survival (PFS) rate was 80.
8%, and 6-month overall survival (OS) rate In 100.
0%, only 4 patients developed cytokine release syndrome (CRS), all of which were grade 1, and no neurotoxicity was observed.
8 patients who reached CR continued to remission at the last follow-up
.
Professor Li Caixia’s interpretation: Although the chimeric antigen receptor-modified T (CAR-T) cell treatment of R/R B-NHL has achieved remarkable success, the higher failure rate and recurrence of some patients after CAR-T cell treatment are Huge obstacles to overcome
.
Among them, T cell dysfunction caused by CAR-T cell depletion is one of the main factors for the failure of CAR-T cell therapy
.
Preclinical models have proven that anti-PD-1 antibodies are an attractive option that can reverse T cell failure after CAR-T treatment
.
Therefore, we used targeted CD19/CD22 CAR-T cells combined with anti-PD-1 monoclonal antibody tislelizumab to treat R/R B-NHL, and explored the effectiveness and safety of the combination therapy, which is R/R B-NHL provides new treatment options and methods
.
Professor Li Caixia, Doctor of Medicine, Doctoral Supervisor, Chief Physician, Department of Hematology, The First Affiliated Hospital of Soochow University Member of the Hematology Oncology Committee of the Cancer Society and member of the Lymphatic Oncology Group CSCO Member of the Chinese Anti-Lymphoma Alliance Deputy Leader of the Hematology Group of Jiangsu Medical Association Member of the Hematology Group of Jiangsu Medical Association Research Background: B-NHL is a group Hematological malignancies derived from B lymphocytes
.
Currently commonly used clinical treatment methods include chemotherapy, radiotherapy, hematopoietic stem cell transplantation, molecular targeted drugs, etc.
Most patients can obtain effective remission after standard treatment, but patients with relapsed or refractory disease are ineffective or unable to treat these conventional treatments.
Obtain long-term relief
.
Research method: A prospective single-arm study was conducted on CAR-T cells combined with anti-PD-1 antibody in the treatment of R/R B-NHL patients (NCT04539444)
.
On the first day (day +1) after the reinfusion of CD19/CD22 second-generation CAR-T cells, the anti-PD-1 antibody tislelizumab was injected intravenously at 200 mg to evaluate the effectiveness and safety of the combination therapy
.
Research results: From August 1, 2020 to June 30, 2021, a total of 11 patients were enrolled and completed at least 3 months of follow-up
.
With a median follow-up of 5.
8 months, 9 of 11 patients achieved overall remission (ORR of 81.
8%), 8 of 11 patients achieved complete remission (CR rate 72.
7%), and all 8 patients achieved CR Remission continued at the last follow-up
.
The 6-month PFS rate and OS rate were 80.
8% and 100.
0%, respectively
.
CRS occurred in only 4 patients, all of which were grade 1, and no neurotoxicity was observed
.
Research conclusions: These results show that CAR-T cells combined with anti-PD-1 antibodies can produce a safe and long-lasting response in R/R B-NHL patients.
It is expected that more patients will be enrolled and long-term follow-up data.
This study is to significantly improve CAR- T therapy combined with PD-1 monoclonal antibody has scientific significance and application prospects for the therapeutic effect of R/R B-NHL and prolong the survival of patients
.
References: 1.
2021 ASH abstract No.
1730 stamp "read the original", we make progress together
As a global event in the field of blood, it will attract the release and display of research results from the field of blood from all over the world every time , The research results of Chinese scholars are also increasing
.
Here we invite Professor Li Caixia from the First Affiliated Hospital of Soochow University to bring us the preliminary results of a study on relapsed and refractory B-cell non-Hodgkin’s lymphoma (R/R B-NHL) at the ASH conference 1
.
Study speed reading: The study included 11 patients who were treated with the anti-PD-1 antibody tislelizumab on the first day after continuous infusion of CD19/CD22 CAR-T cells.
The median follow-up was 5.
8 months.
The overall response rate ( ORR) was 81.
8% (9/11), complete remission (CR) rate was 72.
7% (8/11), 6-month progression-free survival (PFS) rate was 80.
8%, and 6-month overall survival (OS) rate In 100.
0%, only 4 patients developed cytokine release syndrome (CRS), all of which were grade 1, and no neurotoxicity was observed.
8 patients who reached CR continued to remission at the last follow-up
.
Professor Li Caixia’s interpretation: Although the chimeric antigen receptor-modified T (CAR-T) cell treatment of R/R B-NHL has achieved remarkable success, the higher failure rate and recurrence of some patients after CAR-T cell treatment are Huge obstacles to overcome
.
Among them, T cell dysfunction caused by CAR-T cell depletion is one of the main factors for the failure of CAR-T cell therapy
.
Preclinical models have proven that anti-PD-1 antibodies are an attractive option that can reverse T cell failure after CAR-T treatment
.
Therefore, we used targeted CD19/CD22 CAR-T cells combined with anti-PD-1 monoclonal antibody tislelizumab to treat R/R B-NHL, and explored the effectiveness and safety of the combination therapy, which is R/R B-NHL provides new treatment options and methods
.
Professor Li Caixia, Doctor of Medicine, Doctoral Supervisor, Chief Physician, Department of Hematology, The First Affiliated Hospital of Soochow University Member of the Hematology Oncology Committee of the Cancer Society and member of the Lymphatic Oncology Group CSCO Member of the Chinese Anti-Lymphoma Alliance Deputy Leader of the Hematology Group of Jiangsu Medical Association Member of the Hematology Group of Jiangsu Medical Association Research Background: B-NHL is a group Hematological malignancies derived from B lymphocytes
.
Currently commonly used clinical treatment methods include chemotherapy, radiotherapy, hematopoietic stem cell transplantation, molecular targeted drugs, etc.
Most patients can obtain effective remission after standard treatment, but patients with relapsed or refractory disease are ineffective or unable to treat these conventional treatments.
Obtain long-term relief
.
Research method: A prospective single-arm study was conducted on CAR-T cells combined with anti-PD-1 antibody in the treatment of R/R B-NHL patients (NCT04539444)
.
On the first day (day +1) after the reinfusion of CD19/CD22 second-generation CAR-T cells, the anti-PD-1 antibody tislelizumab was injected intravenously at 200 mg to evaluate the effectiveness and safety of the combination therapy
.
Research results: From August 1, 2020 to June 30, 2021, a total of 11 patients were enrolled and completed at least 3 months of follow-up
.
With a median follow-up of 5.
8 months, 9 of 11 patients achieved overall remission (ORR of 81.
8%), 8 of 11 patients achieved complete remission (CR rate 72.
7%), and all 8 patients achieved CR Remission continued at the last follow-up
.
The 6-month PFS rate and OS rate were 80.
8% and 100.
0%, respectively
.
CRS occurred in only 4 patients, all of which were grade 1, and no neurotoxicity was observed
.
Research conclusions: These results show that CAR-T cells combined with anti-PD-1 antibodies can produce a safe and long-lasting response in R/R B-NHL patients.
It is expected that more patients will be enrolled and long-term follow-up data.
This study is to significantly improve CAR- T therapy combined with PD-1 monoclonal antibody has scientific significance and application prospects for the therapeutic effect of R/R B-NHL and prolong the survival of patients
.
References: 1.
2021 ASH abstract No.
1730 stamp "read the original", we make progress together
